HOOKIPA PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8933 USD | +10.82% |
|
+21.87% | +10.28% |
| Apr. 25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
| Apr. 25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 310.7 | 322.4 | 69.8 | 44.32 | 80.15 | 88.39 | - | - |
| Enterprise Value (EV) 1 | 310.7 | 322.4 | 8.894 | -65.66 | 80.15 | 88.39 | 88.39 | 88.39 |
| P/E ratio | -5.07 x | -6.56 x | -1.01 x | -0.82 x | -0.94 x | -1.93 x | -1.81 x | -1.64 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 26 x | 16.5 x | 3.78 x | 3.11 x | 3.98 x | 2.87 x | 7.48 x | 15.2 x |
| EV / Revenue | 26 x | 16.5 x | 3.78 x | 3.11 x | 3.98 x | 2.87 x | 7.48 x | 15.2 x |
| EV / EBITDA | -6,259,736 x | -6,561,357 x | -906,147 x | -637,217 x | - | - | - | - |
| EV / FCF | -7,106,010 x | -7,729,376 x | -888,127 x | -1,326,402 x | - | - | - | - |
| FCF Yield | -0% | -0% | -0% | -0% | - | - | - | - |
| Price to Book | 1.85 x | - | 0.71 x | 0.52 x | - | - | - | - |
| Nbr of stocks (in thousands) | 25,408 | 29,071 | 29,959 | 54,717 | 98,950 | 98,950 | - | - |
| Reference price 2 | 12.23 | 11.09 | 2.330 | 0.8100 | 0.8100 | 0.8933 | 0.8933 | 0.8933 |
| Announcement Date | 3/19/20 | 3/18/21 | 3/24/22 | 3/15/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 11.94 | 19.58 | 18.45 | 14.25 | 20.13 | 30.79 | 11.82 | 5.833 |
| EBITDA | -49.64 | -49.14 | -77.03 | -69.55 | - | - | - | - |
| EBIT 1 | -51.08 | -53.28 | -81.67 | -73.16 | -97.69 | -54.71 | -108.2 | -138 |
| Operating Margin | -427.78% | -272.08% | -442.73% | -513.4% | -485.34% | -177.71% | -915.03% | -2,365.02% |
| Earnings before Tax (EBT) 1 | - | -44.08 | -75.66 | -64.68 | -81.21 | -79.41 | -108.9 | -114.5 |
| Net income 1 | -43.04 | -44.08 | -75.66 | -64.92 | -81.58 | -63.6 | -84.86 | -96.88 |
| Net margin | -360.38% | -225.09% | -410.15% | -455.58% | -405.29% | -206.58% | -717.7% | -1,660.81% |
| EPS 2 | -2.410 | -1.690 | -2.300 | -0.9900 | -0.8600 | -0.4633 | -0.4933 | -0.5450 |
| Free Cash Flow | -43.73 | -41.71 | -78.6 | -33.41 | - | - | - | - |
| FCF margin | -366.19% | -212.98% | -426.05% | -234.5% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/19/20 | 3/18/21 | 3/24/22 | 3/15/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.874 | 3.895 | 1.445 | 2.746 | 2.23 | 7.828 | 3.176 | 2.679 | 6.867 | 7.407 | 5.225 | 12.2 | 6.65 | 6.75 |
| EBITDA | - | -20.82 | - | - | - | -12.68 | - | - | - | - | - | - | - | - |
| EBIT 1 | -21.17 | -22.05 | -20.15 | -18.43 | -20.99 | -13.59 | -22.66 | -21.47 | -22.67 | -30.9 | -11.76 | 0.257 | -8.353 | -9.301 |
| Operating Margin | -546.36% | -566.03% | -1,394.26% | -671.05% | -941.39% | -173.58% | -713.38% | -801.49% | -330.13% | -417.11% | -225.03% | 2.11% | -125.61% | -137.79% |
| Earnings before Tax (EBT) | -20.04 | -21.24 | -17.97 | -16.36 | -18.28 | -12.08 | -19.68 | -18.02 | -19.07 | -24.65 | - | - | - | - |
| Net income 1 | -20.04 | -21.24 | -17.97 | -16.36 | -18.28 | -12.31 | -19.68 | -18.02 | -19.07 | -24.82 | -5.7 | -7.7 | -9.2 | -10.4 |
| Net margin | -517.29% | -545.19% | -1,243.46% | -595.63% | -819.73% | -157.27% | -619.65% | -672.49% | -277.65% | -335.06% | -109.09% | -63.11% | -138.35% | -154.07% |
| EPS 2 | -0.6100 | -0.6400 | -0.4000 | -0.2300 | -0.2500 | -0.1600 | -0.2700 | -0.2200 | -0.1700 | -0.2200 | -0.1233 | -0.0900 | -0.1300 | -0.1267 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/24/22 | 5/16/22 | 8/11/22 | 11/14/22 | 3/15/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/22/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | 60.9 | 110 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -43.7 | -41.7 | -78.6 | -33.4 | - | - | - | - |
| ROE (net income / shareholders' equity) | -36.5% | -32.2% | -61.6% | -67.6% | - | - | - | - |
| ROA (Net income/ Total Assets) | -29.9% | - | - | - | - | - | - | - |
| Assets 1 | 143.7 | - | - | - | - | - | - | - |
| Book Value Per Share | 6.600 | - | 3.270 | 1.560 | - | - | - | - |
| Cash Flow per Share | -2.340 | -1.510 | -2.010 | -0.3100 | - | - | - | - |
| Capex | 2 | 2.37 | 12.6 | 5.02 | - | - | - | - |
| Capex / Sales | 16.74% | 12.11% | 68.2% | 35.21% | - | - | - | - |
| Announcement Date | 3/19/20 | 3/18/21 | 3/24/22 | 3/15/23 | 3/22/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.8933
USD
Average target price
4.6
USD
Spread / Average Target
+414.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.28% | 88.39M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- HOOK Stock
- Financials HOOKIPA Pharma Inc.
